在BRAF突变黑色素瘤中非编码RNA:目标,指标和治疗潜力
S Afsar1, Rahamat Unissa Syed2, Weam M A Khojali3,4
1Department of Virology, Sri Venkateswara University, Tirupathi, Andhra Pradesh, 517502, India. mammoth.afsar1@gmail.com.
Naunyn-Schmiedeberg's archives of pharmacology
|August 21, 2024
概括
非编码RNAs (ncRNAs) 显著调节BRAF突变黑色素瘤,影响癌症生长和治疗耐药性. 准这些ncRNA为新黑色素瘤疗法和生物标志物提供了潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 黑色素瘤是一种侵袭性皮肤癌,通常是由BRAF突变驱动的.
- 像V600E这样的BRAF突变激活了MAPK通路,促进了癌症的生长和治疗抵抗力.
研究的目的:
- 审查非编码RNAs (ncRNAs) 与黑色素瘤中的BRAF突变之间的关系.
- 阐明ncRNAs在BRAF突变黑色素瘤中的调节作用及其对治疗耐药性的影响.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 综合关于ncRNA介导调节和BRAF突变黑色素瘤治疗反应的证据.
主要成果:
- 关键的ncRNAs,包括microRNAs和长ncRNAs,调节黑色素瘤的发展和治疗耐药性.
- 特定的ncRNAs (例如,BANCR,RMEL3) 与MAPK路径相互作用.
- 其他ncRNAs (例如,miR-579-3p,miR-1246) 参与药物耐药性机制,如自和免疫检查点调节.
结论:
- ncRNAs在调节BRAF突变黑色素瘤和耐药性方面发挥着关键作用.
- ncRNAs显示出作为改善黑色素瘤治疗结果的生物标志物和治疗点的潜力.
更多相关视频
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.9K
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
8.7K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
